Company Profiles

driven by the PitchBook Platform

NKT Therapeutics

Description

Developer of therapeutics based on immune cells called natural killer T (NKT) cells. The company develops therapeutics for the treatment of cancer, infectious diseases, autoimmune diseases, asthma and dermatitis.

2008

Founded

PRIVATE

Status

1-10

Employees

Later Stage VC

Latest Deal Type

$2.35M

Latest Deal Amount

$25.6M

Total Amount Raised

Description

Developer of therapeutics based on immune cells called natural killer T (NKT) cells. The company develops therapeutics for the treatment of cancer, infectious diseases, autoimmune diseases, asthma and dermatitis.

Website:

www.nktrx.com

Ownership Status

Privately held (backing)

Financing Status

Venture Capital-Backed

Primary Industry

Biotechnology

Primary Office

880 Winter Street Suite 350 Waltham, MA 02451United States +1 (781) 684-0290
Request a free trial to the PitchBook Platform
You're viewing a free company profile from the PitchBook Platform. To explore NKT Therapeutics's full profile, request a free trial.

NKT Therapeutics Valuation and Funding

Request access
Deal TypeDateAmountRaised to DatePost-ValStatusStage

NKT Therapeutics Cap Table

Stock# of Shares
Authorized
Par ValueDividend Rate (%)Original
Issue Price
LiquidationLiquidation
Pref. Multiple
Conversion
Price
% Owned

NKT Therapeutics Investors (4)

Request access
Investor NameInvestor TypeHoldingInvestor SinceParticipating RoundsBoard
Seat
Contact
Info
CerteonCorporationMinority000 0000000 0000
MedImmune VenturesCorporate Venture CapitalMinority000 0000000 0000
Partners HealthCare InnovationCorporate Venture CapitalMinority000 0000000 0000
SV Life Sciences AdvisersVenture CapitalMinority000 0000000 0000
Certeon Corporation
MedImmune Ventures Corporate Venture Capital
Partners HealthCare Innovation Corporate Venture Capital
SV Life Sciences Advisers Venture Capital

NKT Therapeutics Executive Team (9)

NameTitleBoard
Seat
Contact
Info
Robert Mashal MDPresident, Chief Executive Officer & Board Member
Robert SchaubChief Scientific Officer
Rosemary Mazanet Ph.DChief Medical Officer
Brian WilsonCo-Founder
Mark Exley Ph.DCo-Founder
Robert Mashal MD President, Chief Executive Officer & Board Member
Robert Schaub Chief Scientific Officer
Rosemary Mazanet Ph.D Chief Medical Officer
Brian Wilson Co-Founder
Mark Exley Ph.D Co-Founder

NKT Therapeutics Board Members (9)

NameRepresentingRoleSinceContact
Info
Daniel PetreeSelfBoard Member000 0000
David Hung MDSelfBoard Member000 0000
Edward Mascioli MDSV Life Sciences AdvisersVenture Partner000 0000
Maggie LeFlore Ph.DMedImmune VenturesManaging Director000 0000
Michael Ross Ph.DSV Life Sciences AdvisersManaging Partner000 0000
Daniel Petree Board Member Self
David Hung MD Board Member Self
Edward Mascioli MD Venture Partner SV Life Sciences Advisers
Maggie LeFlore Ph.D Managing Director MedImmune Ventures
Michael Ross Ph.D Managing Partner SV Life Sciences Advisers
Request full access to PitchBook